Clinical Trials Logo

CKD clinical trials

View clinical trials related to CKD.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04983979 Terminated - Clinical trials for Diabetes Mellitus, Type 2

The ORTIZ Study: Optimising RASi Therapy With SZC

ORTIZ
Start date: June 17, 2022
Phase: Phase 2
Study type: Interventional

The hypothesis is that 3 months' treatment with SZC versus placebo will enable RASi (Irbesartan) maximisation in a cohort of patients with diabetic kidney disease.

NCT ID: NCT04741074 Terminated - Obesity Clinical Trials

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

RAISE-KT
Start date: July 23, 2021
Phase: Phase 3
Study type: Interventional

This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.

NCT ID: NCT03277183 Terminated - Anemia Clinical Trials

Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

Start date: November 2, 2017
Phase: Phase 4
Study type: Interventional

Although several large well designed clinical trials have shown that erythropoietin which is commonly used to treat anemia associated with kidney disease, increases the risk of stroke and heart disease, the mechanism for this increased risk is unknown. The investigators' preliminary studies show that the adverse effects of erythropoietin are from activation of the heterodimeric erythropoietin/ beta common receptor which only occurs with high doses of erythropoietin. The investigators propose a clinical trial of 120 patients assigned to low doses of erythropoietin given more frequently or the same cumulative dose of erythropoietin administered as a high dose once every two weeks and assess effects on the beta common receptor activation, inflammation and vascular disease as evidence by MRI of the carotid arteries.